These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Liposomal resiquimod for the treatment of Leishmania donovani infection. Peine KJ; Gupta G; Brackman DJ; Papenfuss TL; Ainslie KM; Satoskar AR; Bachelder EM J Antimicrob Chemother; 2014 Jan; 69(1):168-75. PubMed ID: 23956375 [TBL] [Abstract][Full Text] [Related]
5. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Sinha R; Roychoudhury J; Palit P; Ali N Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907 [TBL] [Abstract][Full Text] [Related]
6. In Vivo and Cellular Trafficking of Acetalated Dextran Microparticles for Delivery of a Host-Directed Therapy for Salmonella enterica Serovar Typhi Infection. Johnson MM; Collier MA; Hoang KV; Pino EN; Graham-Gurysh EG; Gallovic MD; Zahid MSH; Chen N; Schlesinger L; Gunn JS; Bachelder EM; Ainslie KM Mol Pharm; 2018 Nov; 15(11):5336-5348. PubMed ID: 30296381 [TBL] [Abstract][Full Text] [Related]
7. Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection. Hoang KV; Borteh HM; Rajaram MV; Peine KJ; Curry H; Collier MA; Homsy ML; Bachelder EM; Gunn JS; Schlesinger LS; Ainslie KM Int J Pharm; 2014 Dec; 477(1-2):334-43. PubMed ID: 25447826 [TBL] [Abstract][Full Text] [Related]
8. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Paila YD; Saha B; Chattopadhyay A Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487 [TBL] [Abstract][Full Text] [Related]
9. Activity of a novel sulfonamide compound 2-nitro-N-(pyridin-2-ylmethyl)benzenesulfonamide against Leishmania donovani. Dikhit MR; Purkait B; Singh R; Sahoo BR; Kumar A; Kar RK; Ansari MY; Saini S; Abhishek K; Sahoo GC; Das S; Das P Drug Des Devel Ther; 2016; 10():1753-61. PubMed ID: 27307706 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488 [TBL] [Abstract][Full Text] [Related]
11. Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies. Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK Pharm Res; 2015 Aug; 32(8):2663-77. PubMed ID: 25715698 [TBL] [Abstract][Full Text] [Related]
12. Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo. Kar A; Jayaraman A; Charan Raja MR; Srinivasan S; Debnath J; Mahapatra SK Int Immunopharmacol; 2021 Feb; 91():107291. PubMed ID: 33360084 [TBL] [Abstract][Full Text] [Related]
13. Lupeol and amphotericin B mediate synergistic anti-leishmanial immunomodulatory effects in Leishmania donovani-infected BALB/c mice. Das A; Jawed JJ; Das MC; Parveen S; Ghosh C; Majumdar S; Saha B; Bhattacharjee S Cytokine; 2021 Jan; 137():155319. PubMed ID: 33002744 [TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity. Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987 [TBL] [Abstract][Full Text] [Related]
15. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis. Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis. Voak AA; Harris A; Qaiser Z; Croft SL; Seifert K Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630200 [TBL] [Abstract][Full Text] [Related]
17. Novel arylimidamides for treatment of visceral leishmaniasis. Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397 [TBL] [Abstract][Full Text] [Related]
18. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase. Murray HW; Xiang Z; Ma X Am J Trop Med Hyg; 2006 Jun; 74(6):1013-5. PubMed ID: 16760512 [TBL] [Abstract][Full Text] [Related]
19. Antileishmanial activity of nano-amphotericin B deoxycholate. Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526 [TBL] [Abstract][Full Text] [Related]
20. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Petit C; Yardley V; Gaboriau F; Bolard J; Croft SL Antimicrob Agents Chemother; 1999 Feb; 43(2):390-2. PubMed ID: 9925541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]